Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SACT-1 (rilpivirine hydrochloride) is an orally administered repurposed small molecule drug for the treatment of neuroblastoma. SACT-1 enhance tumor cell death and suppress MYCN expression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 22, 2023
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dolutegravir Sodium,Rilpivirine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets
Details : Dolutegravir Sodium, where dolutegravir is an integrase inhibitor while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used as an oral combination for the treatment of HIV-1 infections in treatment-naive patients.
Product Name : Dolutegravir/Rilpivirine-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2023
Lead Product(s) : Dolutegravir Sodium,Rilpivirine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Aenco Technologies Limited
Deal Size : $3.0 million
Deal Type : Private Placement
Aptorum Group Announces Completion of $3 Million Convertible Note due 2023
Details : SACT-1 (rilpivirine) is an orally administered repurposed small molecule drug to target neuroblastoma. SACT-1’s mechanism has been investigated to enhance tumor cell death and suppress MYCN expression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 16, 2022
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Aenco Technologies Limited
Deal Size : $3.0 million
Deal Type : Private Placement
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SACT-1 is an orally administered repurposed small molecule drug to target neuroblastoma. SACT-1’s mechanism has been investigated in our preclinical studies to enhance tumor cell death and suppress MYCN expression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 02, 2022
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : USFDA has granted Orphan Drug Designation to SACT-1, an orally administered repurposed small molecule drug to target neuroblastoma on the basis of results that demonstrated enhanced tumor cell death and suppress MYCN expression in the preclinical studies...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 20, 2022
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : H.C. Wainwright & Co
Deal Size : $9.0 million
Deal Type : Public Offering
Aptorum Group Announces Closing of $9.0 Million Public Offering
Details : Aptorum Group intends to use the net proceeds to conduct further analyses of SACT-1 and ALS-4, currently on track for IND submission to commence Phase 1b/2a clinical trials and undergoing final stages of IND enabling studies for Phase 1 human clinical tr...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 02, 2020
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : H.C. Wainwright & Co
Deal Size : $9.0 million
Deal Type : Public Offering
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Alliance Global Partners
Deal Size : $10.0 million
Deal Type : Public Offering
Aptorum Group Announces Pricing of $10 Million Registered Direct Offering
Details : Net proceeds from the offering will fund the continued research and development of its leading therapeutic candidates (including SACT-1 and ALS-4) into their respective clinical phases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 26, 2020
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Alliance Global Partners
Deal Size : $10.0 million
Deal Type : Public Offering
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptorum Group Announces Significant Progress of SACT-1
Details : Subject to completion of current validation studies, Aptorum Group plans to leverage the 505(b)(2) pathway and submit an IND submission with the FDA for SACT-1 in H2 2020.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 10, 2020
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
